<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2682117-A1" country="EP" doc-number="2682117" kind="A1" date="20140108" family-id="34812855" file-reference-id="312919" date-produced="20180822" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146585429" ucid="EP-2682117-A1"><document-id><country>EP</country><doc-number>2682117</doc-number><kind>A1</kind><date>20140108</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-13004735-A" is-representative="NO"><document-id mxw-id="PAPP154847621" load-source="docdb" format="epo"><country>EP</country><doc-number>13004735</doc-number><kind>A</kind><date>20050117</date><lang>EN</lang></document-id><document-id mxw-id="PAPP191887691" load-source="docdb" format="original"><country>EP</country><doc-number>13004735.0</doc-number><date>20050117</date></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140554931" ucid="CN-200410001748-A" load-source="docdb"><document-id format="epo"><country>CN</country><doc-number>200410001748</doc-number><kind>A</kind><date>20040120</date></document-id></priority-claim><priority-claim mxw-id="PPC140549811" ucid="EP-05700438-A" linkage-type="3" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>05700438</doc-number><kind>A</kind><date>20050117</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL1989321868" load-source="docdb">A61K  31/343       20060101AFI20131129BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989322729" load-source="docdb">A61P   9/10        20060101ALI20131129BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-1801309488" load-source="docdb" scheme="CPC">A61K  31/343       20130101 FI20170613BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132360920" lang="DE" load-source="patent-office">Verwendung von L-Butylphthalid bei der Herstellung von Medikamenten zur Prävention und Behandlung zerebraler Ischämie</invention-title><invention-title mxw-id="PT132360921" lang="EN" load-source="patent-office">The use of L-butylphthalide in the manufacturing of medicines for the prevention and treatment of cerebral ischemia disease</invention-title><invention-title mxw-id="PT132360922" lang="FR" load-source="patent-office">Utilisation de L-butylphtalide pour la fabrication de médicaments pour la prévention et le traitement d'une maladie induite par l'ischémie cérébrale</invention-title><citations><patent-citations><patcit mxw-id="PCIT371081332" load-source="docdb" ucid="CN-1100097-A"><document-id format="epo"><country>CN</country><doc-number>1100097</doc-number><kind>A</kind><date>19950315</date></document-id><sources><source name="SEA" category="ID" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242944109" load-source="docdb" ucid="CN-1257706-A"><document-id format="epo"><country>CN</country><doc-number>1257706</doc-number><kind>A</kind><date>20000628</date></document-id><sources><source name="SEA" category="X" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT377487172" load-source="docdb" ucid="CN-93117148-A" dnum-type="application"><document-id format="epo"><country>CN</country><doc-number>93117148</doc-number><kind>A</kind><date>19930909</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT377483701" load-source="docdb" ucid="CN-98125618-A" dnum-type="application"><document-id format="epo"><country>CN</country><doc-number>98125618</doc-number><kind>A</kind><date>19981218</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT377495426" load-source="docdb" ucid="CN-99109673-A" dnum-type="application"><document-id format="epo"><country>CN</country><doc-number>99109673</doc-number><kind>A</kind><date>19990705</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT371081333" load-source="docdb" ucid="EP-1679070-A1"><document-id format="epo"><country>EP</country><doc-number>1679070</doc-number><kind>A1</kind><date>20060712</date></document-id><sources><source name="SEA" category="E" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT371081334" load-source="docdb" ucid="EP-1757286-A1"><document-id format="epo"><country>EP</country><doc-number>1757286</doc-number><kind>A1</kind><date>20070228</date></document-id><sources><source name="SEA" category="E" created-by-npl="N"/></sources></patcit></patent-citations><non-patent-citations><nplcit><text>CHANG QING ET AL: "Effects of chiral 3-n-butylphthalide on apoptosis induced by transient focal cerebral ischemia in rats", ACTA PHARMACOLOGICA SINICA AUG 2003,, vol. 24, no. 8, 1 August 2003 (2003-08-01), pages 796 - 804, XP002558734</text><sources><source mxw-id="PNPL57485604" load-source="docdb" name="SEA" category="X"/></sources></nplcit><nplcit><text>CHINESE MEDICAL SCIENCES JOURNAL = CHUNG-KUO I HSÜEH K'O HSÜEH TSA CHIH / CHINESE ACADEMY OF MEDICAL SCIENCES JUN 1997, vol. 12, no. 2, June 1997 (1997-06-01), pages 102 - 106, ISSN: 1001-9294</text><sources><source mxw-id="PNPL67455610" load-source="docdb" name="SEA"/></sources></nplcit><nplcit><text>CHONG Z ET AL: "dl-3-n-butylphthalide reduces brain damage in mice with closed head injury.", CHINESE MEDICAL JOURNAL JUL 2000, vol. 113, no. 7, July 2000 (2000-07-01), pages 613 - 616, XP002559419, ISSN: 0366-6999</text><sources><source mxw-id="PNPL57485605" load-source="docdb" name="SEA" category="I"/></sources></nplcit><nplcit><text>CHONG Z Z ET AL: "Effect of dl-n-butylphthalide on the activity of the choline acetyltransferase in ischemic brain and cultured neurons subjected to hypoglycemia/hypoxia", ZHONGGUO YAOXUE ZAZHI - CHINESE PHARMACEUTICAL JOURNAL, GAI KAN BIAN-WEI-HUI, BEIJING, CN, vol. 34, no. 8, 1 August 1999 (1999-08-01), pages 519 - 522, XP008102416, ISSN: 1001-2494</text><sources><source mxw-id="PNPL57485606" load-source="docdb" name="SEA" category="X"/></sources></nplcit><nplcit><text>DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1996, LIN J F ET AL: "Effect of DL-3-N-butylphthalide on delayed neuronal damage after focal cerebral ischemia and intrasynaptosomes calcium in rats", XP002558737, Database accession no. PREV199699158021</text><sources><source mxw-id="PNPL57485607" load-source="docdb" name="SEA" category="I"/></sources></nplcit><nplcit><text>DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; June 2000 (2000-06-01), XIONG JIE ET AL: "The protective effect of butylphthalide against mitochondrial injury during cerebral ischemia", XP002559421, Database accession no. PREV200000498562</text><sources><source mxw-id="PNPL57485608" load-source="docdb" name="SEA" category="X"/></sources></nplcit><nplcit><text>DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 1995, FENG Y P ET AL: "[Effect of DL-butylphthalide (NBP) on mouse brain energy metabolism in complete brain ischemia induced by decapitation]", XP002559422, Database accession no. NLM8701729</text><sources><source mxw-id="PNPL57485609" load-source="docdb" name="SEA" category="I"/></sources></nplcit><nplcit><text>DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 1996, ZHANG L Y ET AL: "[Effect of dl-3-n-butylphthalide (NBP) on life span and neurological deficit in SHRsp rats]", XP002558739, Database accession no. NLM8762459</text><sources><source mxw-id="PNPL57485610" load-source="docdb" name="SEA" category="I"/></sources></nplcit><nplcit><text>DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; December 1995 (1995-12-01), LIU X G ET AL: "[Protective effect of dl-3-n-butylphthalide on ischemic neurological damage and abnormal behavior in rats subjected to focal ischemia]", XP002558738, Database accession no. NLM8712015</text><sources><source mxw-id="PNPL57485611" load-source="docdb" name="SEA" category="I"/></sources></nplcit><nplcit><text>DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; June 1997 (1997-06-01), DENG W ET AL: "Effect of dl-3-n-butylphthalide on brain edema in rats subjected to focal cerebral ischemia.", XP002716864, Database accession no. NLM11324493</text><sources><source mxw-id="PNPL57485612" load-source="docdb" name="SEA" category="I"/></sources></nplcit><nplcit><text>HU D ET AL: "Effect of dl-n-butylphthalide on mermory disturbance induced by focal cerebral ischemia in rats", ZHONGGUO YAOLIXUE YU DULIXUE ZAZHI - CHINESE JOURNAL OF PHARMACOLOGY AND TOXICOLOGY, ZHONGGUO YAOLI XUCHUI, BEIJING, CN, vol. 11, no. 1, 1 February 1997 (1997-02-01), pages 14 - 16, XP008111297, ISSN: 1000-3002</text><sources><source mxw-id="PNPL57485613" load-source="docdb" name="SEA" category="I"/></sources></nplcit><nplcit><text>JUNSHAN YANG; YALUN SU, ACTA PHARMACEUTICA SINICA, vol. 31, 1984, pages 671</text><sources><source mxw-id="PNPL57485614" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>PENG YING ET AL: "Effects of chiral NBP on cerebral infarct volume due to transient focal cerebral ischemia", ZHONGGUO XIN YAO ZAZHI - CHINESE NEW DRUGS JOURNAL, GAI-KAN BIANJIBU, BEIJING, CN, vol. 14, no. 4, 1 January 2005 (2005-01-01), pages 420 - 423, XP001539275, ISSN: 1003-3734</text><sources><source mxw-id="PNPL57485615" load-source="docdb" name="SEA" category="XP"/></sources></nplcit><nplcit><text>WANG XING-WANG: "3-n-Butylphthalide: Cerebral antiischemic", DRUGS OF THE FUTURE, vol. 25, no. 1, January 2000 (2000-01-01), pages 16 - 23, XP002716865, ISSN: 0377-8282</text><sources><source mxw-id="PNPL57485616" load-source="docdb" name="SEA" category="I"/></sources></nplcit><nplcit><text>XU HAOLIANG ET AL: "EFFECTS OF 3-N-BUTYLPHTHALDE ON PIAL ARTEROLES INFOCAL CEREBRAL ISCHEIA RATS", YAO HSUEH HSUEH PAO - ACTA PHARMACEUTICA SINICA, BEIJING, CN, vol. 34, no. 3, 1 March 1999 (1999-03-01), pages 172 - 175, XP008071717, ISSN: 0513-4870</text><sources><source mxw-id="PNPL57485617" load-source="docdb" name="SEA" category="X"/></sources></nplcit><nplcit><text>XU HAO-LIANG ET AL: "Inhibitory effects of chiral 3-n-butylphthalide on inflammation following focal ischemic brain injury in rats", ACTA PHARMACOLOGICA SINICA, vol. 21, no. 5, May 2000 (2000-05-01), pages 433 - 438, XP002716863, ISSN: 0253-9756</text><sources><source mxw-id="PNPL57485618" load-source="docdb" name="SEA" category="X"/></sources></nplcit><nplcit><text>YAN C H ET AL: "Effects of dl-3-n-butylphthalide on regional cerebral blood flow in right middle cerebral artery occlusion rats", ZHONGGUO YAO LI XUE BAO = ACTA PHARMACOLOGICA SINICA MAR 1998,, vol. 19, no. 2, 1 March 1998 (1998-03-01), pages 117 - 120, XP002558745</text><sources><source mxw-id="PNPL57485619" load-source="docdb" name="SEA" category="I"/></sources></nplcit><nplcit><text>YAN C-H ET AL: "Effect of dl-n-butylphthalide on striatum cerebral blood flow in normal and middle cerebral artery occlusion rats", ZHONGGUO YAOLIXUE YU DULIXUE ZAZHI - CHINESE JOURNAL OF PHARMACOLOGY AND TOXICOLOGY, ZHONGGUO YAOLI XUCHUI, BEIJING, CN, vol. 12, no. 1, 1 February 1998 (1998-02-01), pages 36 - 39, XP008111296, ISSN: 1000-3002</text><sources><source mxw-id="PNPL57485620" load-source="docdb" name="SEA" category="I"/></sources></nplcit><nplcit><text>YAO XUE XUE BAO = ACTA PHARMACEUTICA SINICA 1995, vol. 30, no. 10, 1995, pages 741 - 744, ISSN: 0513-4870</text><sources><source mxw-id="PNPL67455611" load-source="docdb" name="SEA"/></sources></nplcit><nplcit><text>YAO XUE XUE BAO = ACTA PHARMACEUTICA SINICA 1996, vol. 31, no. 1, 1996, pages 18 - 23, ISSN: 0513-4870</text><sources><source mxw-id="PNPL67455612" load-source="docdb" name="SEA"/></sources></nplcit><nplcit><text>YAO XUE XUE BAO = ACTA PHARMACEUTICA SINICA DEC 1995, vol. 30, no. 12, December 1995 (1995-12-01), pages 896 - 903, ISSN: 0513-4870</text><sources><source mxw-id="PNPL67455613" load-source="docdb" name="SEA"/></sources></nplcit><nplcit><text>YAOXUE XUEBAO, vol. 31, no. 3, 1996, pages 166 - 170, ISSN: 0513-4870</text><sources><source mxw-id="PNPL67455614" load-source="docdb" name="SEA"/></sources></nplcit><nplcit><text>YAOXUE XUEBAO, vol. 35, no. 6, June 2000 (2000-06-01), pages 408 - 412, ISSN: 0513-4870</text><sources><source mxw-id="PNPL67455615" load-source="docdb" name="SEA"/></sources></nplcit><nplcit><text>YU S R ET AL: "[Facilitated performance of learning and memory in rats by 3-n-butyl phthalide]", ZHONGGUO YAO LI XUE BAO = ACTA PHARMACOLOGICA SINICA SEP 1988, vol. 9, no. 5, September 1988 (1988-09-01), pages 385 - 388, XP002559420, ISSN: 0253-9756</text><sources><source mxw-id="PNPL57485621" load-source="docdb" name="SEA" category="I"/></sources></nplcit></non-patent-citations></citations></technical-data><related-documents><relation type="division"><child-doc ucid="EP-13004735-A"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>13004735</doc-number><kind>A</kind><date>20050117</date></document-id></child-doc><parent-doc ucid="EP-05700438.4"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>05700438.4</doc-number><date>20050117</date></document-id></parent-doc></relation></related-documents><parties><applicants><applicant mxw-id="PPAR919542123" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>SHIJIAZHUANG PHARMA GROUP</last-name><address><country>CN</country></address></addressbook></applicant><applicant mxw-id="PPAR919526395" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>SHIJIAZHUANG PHARMA. GROUP ZHONGQI PHARMACEUTICALTECHNOLOGY (SHIJIAZHUANG) CO., LTD.</last-name></addressbook></applicant><applicant mxw-id="PPAR919009842" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Shijiazhuang Pharma. Group Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.</last-name><iid>100219804</iid><address><street>Zhong-Shan West Road 276, Shijiazhuang</street><city>Hebei 050051</city><country>CN</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR919506000" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>LIU ZHENTAO</last-name><address><country>CN</country></address></addressbook></inventor><inventor mxw-id="PPAR919514253" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>LIU, ZHENTAO</last-name></addressbook></inventor><inventor mxw-id="PPAR919012977" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>LIU, ZHENTAO</last-name><address><street>No. 276 Zhongshan West Road</street><city>050051 Shijiazhuang, Hebei</city><country>CN</country></address></addressbook></inventor><inventor mxw-id="PPAR919509748" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>ZHANG HONGWU</last-name><address><country>CN</country></address></addressbook></inventor><inventor mxw-id="PPAR919512626" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>ZHANG, HONGWU</last-name></addressbook></inventor><inventor mxw-id="PPAR919014201" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>ZHANG, HONGWU</last-name><address><street>No. 276 Zhongshan West Road</street><city>050051 Shijiazhuang, Hebei</city><country>CN</country></address></addressbook></inventor><inventor mxw-id="PPAR919527740" load-source="docdb" sequence="3" format="epo"><addressbook><last-name>NIU ZHANQI</last-name><address><country>CN</country></address></addressbook></inventor><inventor mxw-id="PPAR919524763" load-source="docdb" sequence="3" format="intermediate"><addressbook><last-name>NIU, ZHANQI</last-name></addressbook></inventor><inventor mxw-id="PPAR919011592" load-source="patent-office" sequence="3" format="original"><addressbook><last-name>NIU, ZHANQI</last-name><address><street>No. 276 Zhongshan West Road</street><city>050051 Shijiazhuang, Hebei</city><country>CN</country></address></addressbook></inventor><inventor mxw-id="PPAR919507056" load-source="docdb" sequence="4" format="epo"><addressbook><last-name>SHEN DONGMIN</last-name><address><country>CN</country></address></addressbook></inventor><inventor mxw-id="PPAR919512662" load-source="docdb" sequence="4" format="intermediate"><addressbook><last-name>SHEN, DONGMIN</last-name></addressbook></inventor><inventor mxw-id="PPAR919018177" load-source="patent-office" sequence="4" format="original"><addressbook><last-name>SHEN, DONGMIN</last-name><address><street>No. 276 Zhongshan West Road</street><city>050051 Shijiazhuang, Hebei</city><country>CN</country></address></addressbook></inventor><inventor mxw-id="PPAR919510969" load-source="docdb" sequence="5" format="epo"><addressbook><last-name>WANG RONGDUAN</last-name><address><country>CN</country></address></addressbook></inventor><inventor mxw-id="PPAR919521765" load-source="docdb" sequence="5" format="intermediate"><addressbook><last-name>WANG, RONGDUAN</last-name></addressbook></inventor><inventor mxw-id="PPAR919016502" load-source="patent-office" sequence="5" format="original"><addressbook><last-name>WANG, RONGDUAN</last-name><address><street>No. 276 Zhongshan West Road</street><city>050051 Shijiazhuang, Hebei</city><country>CN</country></address></addressbook></inventor><inventor mxw-id="PPAR919527522" load-source="docdb" sequence="6" format="epo"><addressbook><last-name>FENG XIAOLONG</last-name><address><country>CN</country></address></addressbook></inventor><inventor mxw-id="PPAR919543265" load-source="docdb" sequence="6" format="intermediate"><addressbook><last-name>FENG, XIAOLONG</last-name></addressbook></inventor><inventor mxw-id="PPAR919007613" load-source="patent-office" sequence="6" format="original"><addressbook><last-name>FENG, XIAOLONG</last-name><address><street>No. 276 Zhongshan West Road</street><city>050051 Shijiazhuang, Hebei</city><country>CN</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR919012519" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Wibbelmann, Jobst</last-name><iid>100034117</iid><address><street>Wuesthoff &amp; Wuesthoff Patent- und Rechtsanwälte Schweigerstrasse 2</street><city>81541 München</city><country>DE</country></address></addressbook></agent></agents></parties><international-convention-data><designated-states><ep-contracting-states><country mxw-id="DS549747268" load-source="docdb">AT</country><country mxw-id="DS549750141" load-source="docdb">BE</country><country mxw-id="DS549825301" load-source="docdb">BG</country><country mxw-id="DS549826123" load-source="docdb">CH</country><country mxw-id="DS549750142" load-source="docdb">CY</country><country mxw-id="DS549748767" load-source="docdb">CZ</country><country mxw-id="DS549910058" load-source="docdb">DE</country><country mxw-id="DS549750143" load-source="docdb">DK</country><country mxw-id="DS549750144" load-source="docdb">EE</country><country mxw-id="DS549823194" load-source="docdb">ES</country><country mxw-id="DS549825306" load-source="docdb">FI</country><country mxw-id="DS549825307" load-source="docdb">FR</country><country mxw-id="DS549910059" load-source="docdb">GB</country><country mxw-id="DS549750149" load-source="docdb">GR</country><country mxw-id="DS549748768" load-source="docdb">HU</country><country mxw-id="DS549826124" load-source="docdb">IE</country><country mxw-id="DS549750150" load-source="docdb">IS</country><country mxw-id="DS549825308" load-source="docdb">IT</country><country mxw-id="DS549750151" load-source="docdb">LI</country><country mxw-id="DS549825309" load-source="docdb">LT</country><country mxw-id="DS549747281" load-source="docdb">LU</country><country mxw-id="DS549825314" load-source="docdb">MC</country><country mxw-id="DS549823195" load-source="docdb">NL</country><country mxw-id="DS549823196" load-source="docdb">PL</country><country mxw-id="DS549825315" load-source="docdb">PT</country><country mxw-id="DS549748773" load-source="docdb">RO</country><country mxw-id="DS549823197" load-source="docdb">SE</country><country mxw-id="DS549826125" load-source="docdb">SI</country><country mxw-id="DS549820048" load-source="docdb">SK</country><country mxw-id="DS549747282" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data></bibliographic-data><abstract mxw-id="PA128673601" lang="EN" load-source="patent-office"><p id="pa01" num="0001">The present invention relates to the use of L-butylphthalide in the manufacturing of medicaments for the prevention and treatment of cerebral ischemia-induced disease. Cerebral ischemia of the animals or human induces cerebral infarction, neurological deficit, memory disorder, cerebral edema, cerebral apoplexy, metabolic disorder of energy, changes of cerebral blood flow, and the like. The <i>in vivo</i> experiments show that L-butylphthalide can effectively reduce the above-mentioned adverse symptoms induced by cerebral ischemia.</p></abstract><abstract mxw-id="PA128737757" lang="EN" source="EPO" load-source="docdb"><p>The present invention relates to the use of L-butylphthalide in the manufacturing of medicaments for the prevention and treatment of cerebral ischemia-induced disease. Cerebral ischemia of the animals or human induces cerebral infarction, neurological deficit, memory disorder, cerebral edema, cerebral apoplexy, metabolic disorder of energy, changes of cerebral blood flow, and the like. The  in vivo  experiments show that L-butylphthalide can effectively reduce the above-mentioned adverse symptoms induced by cerebral ischemia.</p></abstract><description mxw-id="PDES63959589" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><p id="p0001" num="0001">This is a divisional application of European patent application <patcit id="pcit0001" dnum="EP05700438A"><text>05 700 438.4 filed on January 17, 2005</text></patcit> (published on October 11, 2006; publication no. <patcit id="pcit0002" dnum="EP1709962A1"><text>EP 1 709 962 A1</text></patcit>); the disclosure of which (claims, description, and drawings) is incorporated herewith by reference in its entirety.</p><heading id="h0001">FIELD OF THE INVENTION</heading><p id="p0002" num="0002">The present invention relates to a new use of L-butylphthalide in the prevention and treatment of cerebral ischemia-induced diseases, particularly to a use of L-butylphthalide in manufacturing the medicaments for the prevention and treatment of cerebral ischemia-induced diseases.</p><heading id="h0002">BACKGROUND OF THE INVENTION</heading><p id="p0003" num="0003">The structure of butylphthalide is represented as the following:
<chemistry id="chem0001" num="0001"><img id="ib0001" file="imgb0001.tif" wi="56" he="47" img-content="chem" img-format="tif"/></chemistry></p><p id="p0004" num="0004">There presents two optical isomers of butylphthalide, which are levo-butylphthalide (<i>l</i>-NBP) and dextraL-butylphthalide (<i>d</i>-NBP), due to the presence of one chiral carbon atom therein. L-butylphthalide may not only be directly obtained by extracting the natural celery seeds, but also be synthesized. Chinese Patent No. <patcit id="pcit0003" dnum="CN99109673"><text>99109673.8</text></patcit> and <nplcit id="ncit0001" npl-type="s"><text>Junshan Yang, Yalun Su, Acta Pharmaceutica Sinica, 1984, 31:671</text></nplcit> both disclose how to obtain L-butylphthalide.</p><p id="p0005" num="0005">Furthermore, Chinese Patent No.<patcit id="pcit0004" dnum="CN98125618X"><text> 98125618.X</text></patcit> discloses the use of L-butylphthalide in manufacturing the medicaments against thrombosis and platelet<!-- EPO <DP n="2"> --> aggregation, and shows clearly that L-butylphthalide has the effect of regulating NOS-NO-cGMP systemic function and arachidonic acid metabolism in the neurocytes post cerebral ischemia. In addition, Chinese Patent No. <patcit id="pcit0005" dnum="CN93117148"><text>93117148.2</text></patcit> discloses the use of racemic butylphthalide in manufacturing the medicaments for the prevention and treatment of cerebral ischemia-induced diseases in the mammals or human beings.</p><p id="p0006" num="0006">The object of the present invention is to find further pharmacological effects of L-butylphthalide via animal assay, and thereby provide a new medical use thereof, so as to use it as a new active ingredient in the pharmaceutical formulations of the future.</p><heading id="h0003">SUMMARY OF THE INVENTION</heading><p id="p0007" num="0007">The object of the present invention is to provide a new use of L-butylphthalide.</p><p id="p0008" num="0008">The present invention relates to the use of L-butylphthalide in manufacturing the medicaments for the treatment of cerebral ischemia-induced diseases in the mammals or human beings.</p><p id="p0009" num="0009">Particularly, the present invention relates to the use of L-butylphthalide in manufacturing the medicaments for the treatment of neurological symptoms caused by cerebral injury-induced cerebral ischemia.</p><p id="p0010" num="0010">Particularly, the present invention relates to the use of L-butylphthalide in manufacturing the medicaments for the treatment of memory disorder induced by cerebral ischemia.</p><p id="p0011" num="0011">Particularly, the present invention relates to the use of L-butylphthalide in manufacturing the medicaments for the treatment of cerebral edema induced by cerebral ischemia.</p><p id="p0012" num="0012">Particularly, the present invention relates to the use of L-butylphthalide in manufacturing the medicaments for the treatment of cerebral apoplexy induced by cerebral ischemia.<!-- EPO <DP n="3"> --></p><p id="p0013" num="0013">Particularly, the present invention relates to the use of L-butylphthalide in manufacturing the medicaments for the treatment of metabolic disorder of energy induced by cerebral ischemia.</p><p id="p0014" num="0014">Particularly, the present invention relates to the use of L-butylphthalide in manufacturing the medicaments for the treatment and prevention of changes of cerebral blood flow in the ischemic region of brain.</p><p id="p0015" num="0015">Particularly, the present invention relates to the use of L-butylphthalide in manufacturing the medicaments for the treatment of behavioral disorder and cerebral infarction induced by permanent cerebral ischemia.</p><p id="p0016" num="0016">Particularly, the present invention relates to the use of L-butylphthalide in manufacturing the medicament for the treatment of disorder of neurological function and cerebral infarction induced by ischemia-reperfusion.</p><p id="p0017" num="0017"><i>In vivo</i> animal experiments show that L-butylphthalide has the following functions:
<ol><li>1. significantly reducing the neural symptoms caused by cerebral injury-induced cerebral ischemia in rats;</li><li>2. reducing memory disorder induced by cerebral ischemia in rats;</li><li>3. reducing cerebral edema induced by cerebral ischemia in rats;</li><li>4. reducing cerebral apoplexy induced by cerebral ischemia in rats;</li><li>5. reducing the metabolic disorder of energy induced by cerebral ischemia in rats;</li><li>6. increasing cerebral blood flow in the ischemic region;</li><li>7. reducing behavioral disorder induced by ischemia in rats;</li><li>8. reducing the cerebral infarct area induced by cerebral ischemia in rats.</li></ol></p><p id="p0018" num="0018">The inventor has completed the present invention on the basis of the above-mentioned <i>in vivo</i> animal experiments.</p><p id="p0019" num="0019">The advantage of the present invention lies in the therapeutic effect of L-butylphthalide on the diseases induced by cerebral ischemia.</p><heading id="h0004">DETAILED DESCRIPTION OF THE INVENTION</heading><!-- EPO <DP n="4"> --><p id="p0020" num="0020">The present invention will be described by the <i>in vivo</i> animal experimental data, in order to make those skilled in the art understood better.</p><p id="p0021" num="0021">Example 1. Effects of L-butylphthalide on neural symptoms induced by cerebral<!-- EPO <DP n="5"> --> injury in rats</p><heading id="h0005">Experimental Animals: male Wistar rats</heading><p id="p0022" num="0022">Experimental Methods: Cerebral injury in rats was caused by allowing a cone-shaped metal object weighed 220g freely fall from a position of 30cm height to strike the skull cap behind the left coronal suture. <i>dl-, d</i>-, and <i>l</i>-NBP(50 mg/kg) and the vehicle (control group) were orally administered after 5 minutes, and the behavioral changes were scored after 24 hours.</p><p id="p0023" num="0023">Experimental Results: Cerebral ischemia-induced neural symptom occurred in rats due to the cerebral injury. After orally administration, neural symptoms in <i>l</i>-NBP group was significantly reduced as compared with the vehicle control, while no significant effect was observed in the case of <i>dl-</i> and <i>d</i>-NBP groups, showing that <i>l</i>-NBP has significant reducing effect on neural symptoms caused by cerebral injury-induced cerebral ischemia.</p><heading id="h0006">Example 2. Effects of L-butylphthalide on memory disorder induced by focal cerebral ischemia</heading><heading id="h0007">Experimental Animal: The same as Example 1.</heading><heading id="h0008">Experimental Equipment: Shuttle box</heading><p id="p0024" num="0024">Experimental Methods:
<ol><li>(1) Rats were trained to acquire learning and memory;</li><li>(2) Artery ligation: Artery ligation was conducted on rats according to the method of Tamura. After 24 hours, the experiment of learning as in step (1) was repeatedly conducted on rats.</li><li>(3) Grouping and administration: the rats were divided into 9 groups, which were normal group, pseudo-operation group, ischemia control group, and groups of <i>dl-, d</i>-, and <i>l</i>-NBP (15 and 30 mg/kg). The rats were orally administered at 15 min after the operation, and the changes of latency of active and passive avoidance response were observed after 24 hours.</li></ol><!-- EPO <DP n="6"> --></p><p id="p0025" num="0025">Experimental Results: As compared with the normal group, the rats in the ischemia control group were observed to apparently lose the memory and have less active avoidance response, showing that the memory disorder occurred. As compared with the vehicle control group, the times of active avoidance of rats in <i>l-</i>NBP group was significantly increased, while such effect was not observed in the case of <i>dl</i>- and <i>d</i>-NBP at all doses, showing that <i>l</i>-NBP has the effect of reducing the memory disorder induced by focal cerebral ischemia.</p><heading id="h0009">Example 3: Effects of L-butylphthalide on cerebral edema induced by cerebral artery ligation in rats</heading><p id="p0026" num="0026">Experimental Animals: the same as Example 1.</p><heading id="h0010">Experimental Equipments: Oxygen analyzer</heading><p id="p0027" num="0027">Experimental Methods: Cerebral edema was induced by the ligation of right middle cerebral artery of rats. After 15 minutes, <i>dl-, d-,</i> and <i>l</i>-NBP (40 and 80 mg/kg) were orally administered. The rats were sacrificed after 24 hours. The forebrain was removed, and the cerebral hemispheres on the left and right side were weighed. Dry weight was obtained by baking for 24 hours under 100°G The weight of water in the brain tissue was thus calculated by subtracting of dry weight from wet weight. Then, the tissues was nitrified for 4 hours, and pH was adjusted by using HCl. Next. The ion selective electrode was connected onto the oxygen analyzer, and the concentrations of Na<sup>+</sup> and K<sup>+</sup> in the brain tissue were measured.</p><p id="p0028" num="0028">Experimental Results: <i>l</i>-NBP group was shown to significantly decrease the content of water and Na<sup>+</sup>, and increase the content of K<sup>+</sup> in the brain in a dose-dependent manner, while <i>d</i>- and <i>dl</i>-NBP groups were shown to have no significant effect, suggesting the /-NBP can significantly reduce cerebral edema induced by focal cerebral ischemia. <i>dl</i>-NBP (80 mg/kg) was shown to decrease the content of water and Na+ and increase the content of K+ in the brain, but the effects had no statistical significance. This result was due to the presence of <i>l</i>-NBP (40 mg/kg) in <i>dl</i>-NBP (80 mg/kg), indicating that the presence of <i>d</i>-NBP in <i>dl</i>-NBP may antagonize the function of <i>l</i>-NBP.<!-- EPO <DP n="7"> --></p><heading id="h0011">Example 4. Effects of L-butylphthalide on cerebral apoplexy in spontaneous hypertension rats</heading><heading id="h0012">Experimental Animals: spontaneous hypertensive rats of 6 weeks old</heading><p id="p0029" num="0029">Experimental Methods: Spontaneous hypertensive rats of 6 weeks old were divided into 8 groups with 10 rats per group. 0.8 to 0.9 g per day of common salt was administered starting from week 6. The amount of common salt was gradually increased up to 1.2 to 1.3 g per day. <i>dl-, d</i>-, and <i>l</i>-NBP (25 and 50 mg/kg/d), vehicle (control group) and Nimodipine (37 mg/kg/d) were orally administered respectively starting from week 8 till to 3 weeks after the occurrence of cerebral apoplexy. The scores of neurological deficit and the time of death were recorded.</p><p id="p0030" num="0030">Experimental Results: <i>l</i>-NBP was shown to significantly delay the time of the occurrence of cerebral apoplexy as compared with the vehicle control, indicating that it has the effect of preventing the occurrence of cerebral apoplexy. Furthermore, <i>l</i>-NBP was shown to significantly increase the viability after the occurrence of cerebral apoplexy and reduce neurological deficit in a dose-dependent manner, indicating that it has therapeutic effect on cerebral apoplexy induced by spontaneous hypertension. <i>dl</i>-NBP merely had such effect at relatively high doses, and the effect of which was similar with that of Nimodipine, indicating that the effect of <i>l</i>-NBP is higher than that of <i>dl</i>-NBP. The effect of <i>d</i>-NBP was not significant, suggesting that <i>l</i>-NBP has preventive and therapeutic effect on cerebral apoplexy induced by severe hypertension in the patients.</p><heading id="h0013">Example 5. Effects of L-butylphthalide on ischemic cerebral metabolism of energy induced by the decapitation of mice</heading><heading id="h0014">Experimental Animals: KunMing mice</heading><p id="p0031" num="0031">Test drug: injectable L-butylphthalide was formulated into an emulsion with Tween-80<!-- EPO <DP n="8"> --></p><p id="p0032" num="0032">Experimental Methods: KunMing mice of 10 to 22 g were divided into 8 groups with 10 mice per group. <i>dl-, d</i>-, and <i>l</i>-NBP (50 and 100 mg/kg/d), sodium Phenobarbital (225 mg/kg ip.) and the vehicle were orally administered. Thirty minutes after administration, the mice were decapitated. The time between the decapitation and homogenation, which was 15 seconds, was regarded as cerebral ischemic time. Centrifugation and isolation were conducted by the method of Folbergrova, and the contents of lactic acid, ATP and PCr were determined by enzymological method.</p><p id="p0033" num="0033">Experimental Results: In ischemic control group, the content of lactic acid in the brain was increased, and the contents of ATP and PCr were decreased. In positive control drug group (ip.), the content of lactic acid was significantly decreased, while the contents of ATP and PCr were increased. After oral administration of 50 and 100 mg/kg of <i>l</i>-NBP, the content of lactic acid was significantly decreased, while the contents of ATP and PCr were increased. The difference was very significant as compared with the control group. <i>dl</i>- and <i>d</i>-NBP groups had no such significant effect. The results show that <i>l</i>-NBP has the effect of improving the cerebral metabolism of energy.</p><heading id="h0015">Example 6. Effects of NBP on focal cerebral blood flow</heading><heading id="h0016">Experimental Animals: Male wistar rats</heading><p id="p0034" num="0034">Experimental Equipments: SXP operating microscope, 62TZ-V model high frequency electrotome, solid positioner, Diamond Electro-Tech chemical microsensor 1231, two channel physiological parameter recorder</p><p id="p0035" num="0035">Experimental Methods:
<ol><li>(1) <i>dl-, d</i>-, and <i>l</i>-NBP (15 and 30 mg/kg) and the vehicle were orally administered to the normal rats, and the changes of cerebral blood flow at different time after the administration were measured.</li><li>(2) ligation of cerebral artery was conducted on rats according to the method of Tamura. Oral administration was performed at 10 min after the operation. The rats<!-- EPO <DP n="9"> --> were divided into 9 groups, which were normal group, pseudo-operation group, vehicle control group, and groups of <i>dl-, d</i>-, and <i>l</i>-NBP (15 and 30 mg/kg).</li></ol></p><p id="p0036" num="0036">Experimental Results: The cerebral blood flow rate in the normal rats was significantly increased at 30 minutes after the administration of <i>l</i>-NBP. The cerebral blood flow rate was maintained at a relative high level till to 50 min after the administration, and the increasing extent was gradually decreased over the time, without any effect on the blood pressure. <i>dl</i>- and <i>d</i>-NBP had no such effects, indicating that <i>l</i>-NBP may increase cerebral blood flow and improve cerebral blood supply without substantially affecting the blood pressure. After the ligation of artery, <i>l</i>-NBP (15 and 30 mg/kg) groups could significantly increase the focal blood flow in the corpus striatum, on the side of which the cerebral artery was blocked. The difference was significant as compared with the vehicle control group. In addition, there was also significant difference between the different amounts of drug, showing that the effect of <i>l</i>-NBP is dose-dependent. There was a similar increase in <i>dl</i>-NBP (30 mg/kg) group, but the effect had no statistical significance. No significant effect was observed in other test drug groups. The result showing that <i>l</i>-NBP can not only increase the normal cerebral blood flow, but also increase the blood flow in the ischemic region.</p><heading id="h0017">Example 7. Effects of L-butylphthalide on behavioral disorder and cerebral infarct area in permanent cerebral ischemic rats</heading><heading id="h0018">Experimental Animal: The same as Example 1</heading><p id="p0037" num="0037">Experimental Equipments: COOLPIX955 digital camera, 722 grating spectroscope, XHF-1 high-speed disperser, YKH-II liquid high-speed mixer, WZ-50C2 micro infusion pump</p><p id="p0038" num="0038">Experimental Methods: Wistar rats were anesthetized by intraperitoneally injecting 12% chloral hydrate in 350 mg/kg, and fixed in lateral decubitus position. The skin at the midpoint on the line from exterior auditory canal to canthus was cut. The muscle was separated layer by layer to expose zygomatic arch and the squamous part of temporal bone. The zygomatic arch was scissored and then placed under<!-- EPO <DP n="10"> --> an operating microscope. A window of 2 mm diameter was drilled by using a dentistry drill at a position of 2 mm under the anterior joint between zygomatic arch and the squamous part of temporal bone, so as to expose the middle cerebral artery. A little piece of filter paper was applied onto the middle artery, and 10 µl of 50% FeCl<sub>3</sub> aqueous solution was dripped onto the filter paper. The filter paper was removed after 30 min, and washed with physiological brine. Two to three drops of penicillin (1.6 x 10<sup>5</sup> U/mL) were added so as to prevent infection of the cut. Then the cut was sutured layer by layer.</p><heading id="h0019">Experimental Results:</heading><heading id="h0020">1. Effects on the neurological function</heading><p id="p0039" num="0039">The behavior of animals in pseudo-operation group was not significantly changed, and the scores in model control group were significantly different from those in pseudo-operation group (P&lt;0.001). The improvement of the neurological deficit scores was observed after intravenously injection of <i>l</i>, <i>dl</i> and <i>d</i>-NBP in rats, as compared with model control group. At 24 hours after the administration of dl-NBP at low, moderate and high doses, the scores were decreased by 15.6%, 21.9% and 37.5% respectively, with ED<sub>30</sub> of 7.2 mg/kg. In the case of <i>l</i>-NBP, the scores were decreased by 17.2%, 29.7% and 35.9% respectively, with ED<sub>30</sub> of 6.2 mg/kg. In the case of <i>d</i>-NBP, the scores were decreased by 17.2%, 21.9% and 28.1% respectively, with ED<sub>30</sub> of 12.4 mg/kg. The effect of <i>l</i>-NBP was two times of that of d-NBP. The effect of the positive drug, Nimodipine, was significant.</p><heading id="h0021">2. Effects on cerebral infarct area</heading><p id="p0040" num="0040">The infarct area in the animals of model group was significantly increased as compared with that in the animals of pseudo-operation group. <i>dl</i>-NBP and <i>d</i>-NBP at the dose of 2.5 mg/kg was shown to have the tendency of reducing cerebral infarct area, but the effect was not significant. <i>l</i>-NBP was shown to significantly reduce cerebral infarct area in the cerebral ischemic rats. 5 and 10 mg/kg doses of <i>l</i>-NBP were show to significantly reduce cerebral infarct area of model rats, and the effect increased with the increasing of the dose. As compared with the model control group, three doses of <i>dl</i>-NBP reduced cerebral infarct area by 29.2%, 35.2% and 44.4% respectively, with ED<sub>40</sub> of 7.1 mg/kg. Three doses of <i>l</i>-NBP reduced cerebral infarct area by 38.4%, 41.9% and 50.7% respectively, with ED<sub>40</sub><!-- EPO <DP n="11"> --> of 3.3 mg/kg. Three doses of <i>d</i>-NBP reduced cerebral infarct area by 27.2%, 32.7% and 39.9% respectively, with ED<sub>40</sub> of 10.3 mg/kg. As calculated by converting into ED<sub>50</sub>, the effect of <i>l</i>-NBP was about 3.1 times of that of d-NBP. The effect of the positive drug, Nimodipine, was significant.</p><heading id="h0022">Example 8. Effects of L-butylphthalide on the behavioral disorder and cerebral infarct area in the cerebral ischemia-reperfusion rats</heading><heading id="h0023">Experimental Animal: The same as Example 1</heading><heading id="h0024">Experimental Equipments: The same as Example 7</heading><p id="p0041" num="0041">Experimental Methods: The rats were anesthetized, and fixed in lateral decubitus position. Under the operating microscope, a midline neck skin incision was made to expose the left common cartotid artery. The surrounding nerves and fascia from the bifurcation of common carotid artery to the vascular of basis cranii were removed. Then, the branches of the external carotid artery, which were occipital artery, superior thyroid artery, lingual artery and maxillary artery, were sequentially separated, ligated and scissored. The internal carotid artery was then separated and carefully separated free from vagus nerve. Pterygopalatine artery was ligated at the root of the internal carotid artery. A 6# needle for injection containing 3# nylon suture (diameter of 0.285 mm) was punctured into the free end of the external carotid artery, advancing the nylon suture into the blood vascular. The needle was carefully withdrawn, and the nylon suture was guided into the internal carotid artery from the distal end of the external carotid artery up till to Willis ring, so as to effectively block the middle cerebral artery. Depending on the body weight, the distance from the inserted nylon suture to the bifurcation of common carotid artery was 18 to 20 mm. The free end of the external carotid artery and the nylon suture therein were ligated together, in order to prevent bleeding. The muscle and the skin were then sutured layer by layer, and penicillin was dropped to prevent infection. To effectively block the middle cerebral artery, the tip of the nylon suture was made round by burning with the flame, and coated with 0.1% of poly-L-lysine. The nylon suture was baked in the 60°Coven for 1 hour. Due to the ability of poly-L-lysine to binding the cell and the protein to the plastic surface, and<!-- EPO <DP n="12"> --> thus allow the negative charged nylon suture changing into a positive charged one and attract the anion ionic part of the endothelial cell, the nylon suture was closely bond to the endothelial surface, so as to prevent the leakage of the blood from the surrounding of the suture. Only the internal carotoid artery was separated from the animals of pseudo-operation group. One hour after MCAO, the rats which did not show significant hemiplegia of upper limbs and which subsequently died were wed out. At 1.5 hours after the initiation of MCAO, the nylon suture within the lumen of the internal carotoid artery was carefully withdrawn, and the internal carotoid artery was allowed to reperfusion. The rats were then placed back into the cage.</p><heading id="h0025">Experimental Results:</heading><heading id="h0026">1. Effects on the neurological function</heading><p id="p0042" num="0042">The behavior of animals in pseudo-operation group was not significantly changed, while the scores in animals of model control group were significantly different from those in pseudo-operation group (P&lt;0.001). The improvement of the neurological deficit scores was observed at 24 hours after intravenously injection of <i>l</i>, <i>dl</i>, and <i>d-</i>NBP. The potency of <i>l</i>, <i>dl</i>, and <i>d</i>-NBP had no significant difference. The effect of the positive drug, Nimodipine, was significant.</p><heading id="h0027">2. Effects on cerebral infarct area</heading><p id="p0043" num="0043">The infarct area in animals of model group was significantly increased as compared with that in pseudo-operating group. Intravenously administration of <i>dl</i>, <i>l</i>, and <i>d</i>-NBP were all shown to significantly reduce cerebral infarct area in the cerebral ischemia-reperfusion rats, and the effect increase with the increasing of the dose. As compared with the model control group, three doses of <i>dl</i>-NBP reduced cerebral infarct area by 37.9%, 48.5% and 59.2% respectively, with ED<sub>50</sub> of 5.5 mg/kg. Three doses of <i>l</i>-NBP reduced cerebral infarct area by 40.8%, 57.0% and 68.5% respectively, with ED<sub>50</sub> of 3.8 mg/kg. Three doses of dl-NBP reduced cerebral infarct area by 34.8%, 46.5% and 60.9% respectively, with ED<sub>50</sub> of 5.7 mg/kg. As calculated by ED<sub>50</sub>, the effect of <i>l</i>-NBP was about 1.5 times of that of <i>d</i>-NBP. The effect of the positive drug, Nimodipine, was significant.</p></description><claims mxw-id="PCLM56982634" lang="EN" load-source="patent-office"><!-- EPO <DP n="13"> --><claim id="c-en-0001" num="0001"><claim-text>Use of L-butylphthalide in manufacturing the medicaments for the treatment of cerebral ischemia-induced diseases.</claim-text></claim><claim id="c-en-0002" num="0002"><claim-text>Use of L-butylphthalide in manufacturing medicaments for the prevention of cerebral ischemia-induced diseases.</claim-text></claim></claims><search-report-data><doc-page id="srep0001" file="srep0001.tif" wi="161" he="233" type="tif"/><doc-page id="srep0002" file="srep0002.tif" wi="164" he="233" type="tif"/><doc-page id="srep0003" file="srep0003.tif" wi="164" he="233" type="tif"/><doc-page id="srep0004" file="srep0004.tif" wi="162" he="233" type="tif"/><doc-page id="srep0005" file="srep0005.tif" wi="161" he="233" type="tif"/><doc-page id="srep0006" file="srep0006.tif" wi="162" he="233" type="tif"/><doc-page id="srep0007" file="srep0007.tif" wi="164" he="233" type="tif"/><doc-page id="srep0008" file="srep0008.tif" wi="165" he="232" type="tif"/></search-report-data><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
